Cancer Model Development Centers
Cancer Model Development Centers (CMDCs)
The Cancer Model Development Centers (CMDCs) are tasked with producing next-generation cancer models from clinical samples. Many of the cancer models will encompass tumor types that are rare, originate from patients from underrepresented populations, or lack precision therapy. These models will be annotated with clinical and genomic data and will become community resource.
- Broad Institute: The Broad Institute of Harvard and MIT co-Directors are Dr. Jesse S. Boehm and Dr. Keith L. Ligon.
- Cold Spring Harbor Laboratory: The Principal Investigator for the CSHL CMDC is Dr. David A. Tuveson.
Associated Clinical and Sequence Data
Normal tissue, originating tumor, and the derived models (early and late passage*) will be sequenced by the Genome Characterization Center using the following approaches:
- Whole Genome Sequencing (15X): Provides the DNA sequence of the entire genome. Analysis of the data identifies structural alterations, such as translocations and inversions and somatic copy number alterations.
- Whole Exome Sequencing (150X): Provides DNA sequence of almost all of the known protein-coding regions of the genome (exome). Analysis of the data identifies somatic alterations, including indels and single point mutations.
- Transcriptome Sequencing (RNA-seq): Provides RNA sequence from transcribed genes. Analysis of the data identifies mutations in the protein-coding regions of the genome and a variety of alterations, including novel gene fusions, alternatively spliced isoforms, and variations in gene expression.
*Early is defined as the time when enough cells are obtained so that 10 vials can be shipped to the distributor once the model is fully validated. Late is defined as the time when the distributor expanded the models and froze enough models for distribution. This process ensures that the molecular characteristics of the distributed model as compared to the early passage freeze and to the primary tumor.
Models will also be annotated with clinical data. Once generated, sequence and clinical data from US-derived models will be available through the Genomic Data Commons.
All data will be made available in a way that protects patient privacy.